Bacteremia caused by antimicrobial resistant Campylobacter species at a medical center in Taiwan, 1998–2008

菌血症 弯曲杆菌 抗菌剂 中心(范畴论) 医学 微生物学 生物 细菌 抗生素 化学 结晶学 遗传学
作者
Chun-Hsing Liao,Chia-Yunn Chuang,Yu-Tsung Huang,Ping‐Ing Lee,Po‐Ren Hsueh
出处
期刊:Journal of Infection [Elsevier BV]
卷期号:65 (5): 392-399 被引量:21
标识
DOI:10.1016/j.jinf.2012.06.014
摘要

This study was intended to delineate the clinical and microbiological characteristics of patients with bacteremia caused by Campylobacter species.Twenty-four patients with Campylobacter bacteremia were treated at the National Taiwan University Hospital from 1998 to 2008. All isolates from the 24 patients were confirmed to the species level by multiplex PCR (cadF, hipO and asp gene) and 16S RNA gene sequencing.Bacteremia was caused by Campylobacter coli in 15 (62.5%) patients, Campylobacter fetus in 6 (25%), and Campylobacter jejuni in 3 (12.5%). Of the 24 patients, 16 were male. The major underlying conditions included chronic renal insufficiency (41.7%), liver cirrhosis (37.5%), malignancy (33.3%), and previous abdominal surgery (33.3%). The most common infections were intra-abdominal infection (54.2%), followed by primary bacteremia (41.7%), and cellulitis (4.2%). The mean Pittsburgh bacteremia score was 2.5 (range, 0-9). During the bacteremic episodes, six (25%) patients developed septic shock. Third-generation cephalosporins were administered to 12 (50%) patients as empirical therapy. All-cause mortality was 4.2% at 14 days and 12.5% at 30 days. The majority of the isolates were resistant to third-generation cephalosporins and quinolones, with minimum inhibitory concentration (MIC(90)) values of 32 mg/L for cefotaxime, 128 mg/L for ceftriaxone, and 32 mg/L for both ciprofloxacin and levofloxacin. All isolates possessed a parC mutation (Arg-139-Gln) and 15 exhibited an additional gyrA mutation (Thr-86-Ile). Among these isolates, 20.8% were susceptible to erythromycin (MIC≤0.5 mg/L).Bacteremia caused by antimicrobial resistant Campylobacter species is alarming although the mortality rate is low.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
Rain发布了新的文献求助30
1秒前
2秒前
2秒前
宋万里发布了新的文献求助10
3秒前
4秒前
4秒前
月与海完成签到,获得积分10
4秒前
OIIII完成签到,获得积分10
4秒前
沧笙踏歌发布了新的文献求助30
5秒前
5秒前
嘟嘟发布了新的文献求助10
5秒前
5秒前
5秒前
111发布了新的文献求助10
6秒前
6秒前
6秒前
细腻听白发布了新的文献求助10
8秒前
无招发布了新的文献求助10
8秒前
bkagyin应助zmmz采纳,获得10
8秒前
aara完成签到,获得积分10
9秒前
cdercder应助希尔采纳,获得10
9秒前
不安水蓝发布了新的文献求助10
9秒前
10秒前
失眠世立完成签到 ,获得积分10
11秒前
ZHD发布了新的文献求助10
11秒前
少年发布了新的文献求助10
12秒前
xuxu发布了新的文献求助10
12秒前
情怀应助科研通管家采纳,获得10
12秒前
慕青应助科研通管家采纳,获得10
12秒前
12秒前
Orange应助科研通管家采纳,获得30
13秒前
脑洞疼应助科研通管家采纳,获得10
13秒前
上官若男应助科研通管家采纳,获得10
13秒前
13秒前
13秒前
忧郁的店员完成签到 ,获得积分10
14秒前
Clare完成签到,获得积分10
15秒前
科研通AI6.1应助是丹丹呀采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6960518
求助须知:如何正确求助?哪些是违规求助? 8643289
关于积分的说明 18329842
捐赠科研通 6409080
什么是DOI,文献DOI怎么找? 3085609
关于科研通互助平台的介绍 2133775
邀请新用户注册赠送积分活动 2062172